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EDITORIAL
Arthritis Pain: Moving Between Early- and Late-Stage Disease
David A. Walsh
Joint pain remains the main problem for people
with arthritis, despite availability of an increasing range of
analgesic medications acting through discrete molecular
targets. Existing treatments can relieve pain for some but
not all people with arthritis, some but not all of the time.
There remains a pressing need for better treatments to
reduce the distress and disability of arthritis pain. Pain,
however, also importantly warns us about and protects us
from injury, and painkillers therefore need to target patho-
logic pain in the right people at the right times. In this issue
of Arthritis & Rheumatology, Miller et al (1) provide impor-
tant evidence that different types of pain might respond
differently to the pharmacologic manipulation of a single
analgesic target at various stages in the development of
experimental osteoarthritis (OA) in mice. These preclinical
findings resonate with observations in people with arthritis,
and they point the way to how animal models and sophisti-
cated interventional and measurement techniques might
lead to new treatments and to more effective use of existing
treatments in the foreseeable future.
Miller et al chose to explore pain transmitted
through the abundant subset of articular sensory primary
afferents that express voltage-gated sodium channel 1.8
(NaV1.8). Using designer receptors exclusively activated by
a designer drug technology, they selectively stimulated Gi/o
protein signaling in order to reduce peripheral sensory
nerve activity. They found that they could reduce pain
behaviors at various time points after surgical destabiliza-
tion of the medial meniscus (DMM) in mice, sometimes to
an extent similar to the analgesic effects observed with
morphine.Morphine also activates Gi/o proteins, but across
a wider range of nerve types in the peripheral and central
nervous systems. All of this is as might have been expected.
Perhaps more importantly, Miller and colleagues’ carefully
conducted studies reveal that the effects of pharmacologic
activation of Gi/o varied according to the type of pain
behavior measured and the time since DMM surgery.
Indeed, significant analgesic effects were only observed
before 12 weeks after surgery, and not at 16 weeks, a time
point generally considered to represent late-stage OA in
humans. In contrast, an analgesic acting on both peripheral
and central nerves was able to inhibit pain behaviors at all
time points.
Pain is not a single and homogeneous experience,
and people with arthritis describe different types of pain,
including pain on weight bearing, joint movement, or at
rest, as well as aching pains or burning pains. Different pain
qualities might well reflect different underlying pain mech-
anisms (2). Pain quality is not measurable in animal mod-
els, but various pain behaviors have also been associated
with different pathophysiologic mechanisms. A reduced
threshold for paw withdrawal from a normally non-noxious
punctate stimulus has been associated with evidence of cen-
tral sensitization in rodents and is consistent with low pain
thresholds to mechanical stimuli distal to an OA joint in
humans (3). Reduced threshold to mechanical pressure on
amouse’s kneemightmodel increased joint line tenderness
in human arthritis, a characteristic interpreted in rheuma-
toid arthritis as a sign of active synovitis. Miller and
colleagues’ data suggest that both of these types of pain
might at least sometimes be dependent on NaV1.8-
expressing peripheral sensory nerves and suppressible by
Gi/o activation.
Unfortunately, many analgesic interventions that
have shown great promise in animal models have failed to
impress through randomized controlled trials in arthritis in
humans. Many explanations have been proposed for this
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lack of translational success from laboratory to clinic.
Clearly, humans are different from mice, and pain mecha-
nisms in humans might differ fundamentally from those in
rodents. Animal models of arthritis pain are designed to
minimize suffering of the animal, and the protracted time
course of human arthritis is ideally avoided in experimental
studies. Miller and colleagues’ data highlight that findings
in mouse models might also not translate to other time
points within the same model. In the same way, effective
analgesics in acute pain in humans might not provide bene-
fit for chronic arthritis pain. Opiates, which also act
throughGi/o proteins, are effective in acute musculoskeletal
pain but have limited and typically only very partial benefit
for chronic pain in humans, for example, in OA or low
back pain. Their underwhelming benefit might partly be
attributed to tolerance with chronic use and to adverse
events. It is also important to consider that they might not
work simply because different pain mechanisms are at play.
So what additional mechanisms might contribute to
chronic arthritis pain? Miller et al rightly draw attention to
possible central painmechanisms.Arthritis pain is probably
not often centrally initiated, in contrast to chronic pain after
cerebrovascular accident. Central mechanisms can, how-
ever, importantly augment evoked pain, both allodynia
(pain in response to a normally non-noxious stimulus) and
hyperalgesia (increased pain experienced with a standard-
ized noxious stimulus). Evoked pain requires an intact
peripheral sensory system, and therefore allodynia and
hyperalgesia can be inhibited by peripherally acting anal-
gesics as well as by agents targeting central pain processing.
Inhibiting NaV1.8-expressing neurons increased paw with-
drawal thresholds during the early phases of the DMM
model, again demonstrating that at least some centrally
augmented pain might be improved by peripherally acting
analgesics. Evidence of central sensitization is commonly
observed in severe, late-stage OA in humans but does not
preclude pain relief from joint replacement surgery, an
intervention specifically designed to reduce peripheral
nociceptive inputs. However, not all people undergoing
arthroplasty experience adequate pain relief, suggesting
that non-nociceptive inputs from the postsurgical joint
might continue to be sufficient to activate central pain path-
ways (allodynia). With increasing chronicity, central pain
augmentation might lose its dependence on peripheral
nociceptive input, perhaps due to structural change within
the central nervous system (4) or long-lasting functional
change, as might be driven by epigenetic modifications (5).
Identifying these mechanisms of chronicity could lead to
novel interventions that maintain capacity for neuronal
plasticity and permit reversal of chronic pain.
Another possibility is that peripheral pain mecha-
nisms change during the progression of arthritis. Miller et al
comment on a predominant role of inflammation in the
early stages of the DMM model. Synovitis is also a charac-
teristic of established OA in humans; it is associated with
OA pain (6), and pain relief may be achieved at least in
some patients through antiinflammatory medications
(either delivered systemically or by intraarticular injection).
The contribution of subchondral bone to OA pain might
vary between early and late disease, when the osteochondral
junction is breached and bonemarrow lesions are associated
with regions of cartilage defects (7). Sensory nerve terminals
might eventually grow into articular structures that are not
innervated in the normal joint, for example, in the inner
regions of kneemenisci or in noncalcified articular cartilage,
becoming exposed to unaccustomed mechanical or chemi-
cal stimuli (8). Gene expression patterns in dorsal root gan-
glia also change through the development of arthritis (9,10),
and Gi/o activation might have less potential to inhibit noci-
ceptive drive once different nerve types and signaling path-
ways become recruited. Better understanding of peripheral
painmechanismsmight lead to novel treatments for chronic
arthritis pain. If those mechanisms are specific for chronic
(pathologic) rather than acute pain, analgesics might be
developed that do not impair normal protective responses
(and might even lack acute analgesic efficacy) despite offer-
ing relief to those with chronic arthritis.
Animal models are developed to mimic a particular
human condition, and the DMM model was devised to
resemble human OA. It reflects how internal derangement
in human knees can lead to OA, although the time course
for OA development in humans is usually much more pro-
tracted than that observed in mice. Indeed, by 16 weeks, the
histologic, molecular, and behavioral characteristics of the
DMM model closely resemble those of late-stage human
OA. It is less clear, however, to what extent pathologic
changes shortly after surgery reflect those in the more com-
mon, idiopathic forms of OA seen in humans. Despite these
reservations, the early time points in the pathogenesis of the
DMM model might give useful insights into other painful
articular conditions, for example, sports injuries and inflam-
matory joint disease. Specific analgesic approaches might
only be effective at specific times for specific symptoms in
OA, but they might additionally be effective for other diag-
nostic groups that share discrete painmechanisms.
Miller and colleagues are to be congratulated for
their well-designed and thought-provoking research. Like
much of the best research, it might raise more questions
than are answered, but the direction of travel is clear.
Each increment to our understanding is leading us to bet-
ter explain why different people might respond differently
to the same intervention and, ultimately, who will be most
likely to benefit from which interventions and when.
What can be seen by some as inconsistency or lack of
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robust translational validity in animal models might better
be seen as modeling the heterogeneity of the human expe-
rience of arthritis pain. Understanding this heterogeneity
should lead us ever closer to a more effective and person-
alized approach to rheumatology.
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